Table 1.

Subgroup analyses from phase III trial of bortezomib vs pegylated liposomal doxorubicin + bortezomib (PLD+B)

Subgroup	ORR (%)		TTP (days)		p value
	B	PLD+B	B	PLD+B
Age ≥ 65 yrs	39	49	205	276	0.0056
β2-microglobulin ≥5.5mg/L	33	49	178	276	0.0007
Primary refractory disease	48	43	189	MNR	0.0322
No prior ASCT	39	45	197	331	0.0009
Prior ASCT	46	50	197	276	0.0011
≥2 prior lines of therapy		N/A	186	276	<0.0001
1 prior line of therapy		N/A	199	330	0.036
Anthracycline naïve		N/A	197	282	0.015
Anthracycline exposed		N/A	197	295	0.0001
ISS stage 3		N/A	177	276	<0.0007
ISS stage 2		N/A	186	250	<0.004
ISS stage 1		N/A	223	331	0.067
TSD >2 years		N/A	197	295	<0.0001
TSD ≤2 years		N/A	197	243	0.0033
Relapse <12 months post	74	93	205	276	0.13
ASCT		(p = 0.01)

Abbreviations: ASCT, autologous stem cell transplant; ISS, International Staging System; MNR, median not reached; N/A, not available; TSD, time since diagnosis; TPP, time to disease progression; ORR, overall response rate.